132 related articles for article (PubMed ID: 16253811)
21. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo.
Kennel SJ; Woodward JD; Rondinone AJ; Wall J; Huang Y; Mirzadeh S
Nucl Med Biol; 2008 May; 35(4):501-14. PubMed ID: 18482688
[TBL] [Abstract][Full Text] [Related]
22. A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?
de Kruijff RM; Wolterbeek HT; Denkova AG
Pharmaceuticals (Basel); 2015 Jun; 8(2):321-36. PubMed ID: 26066613
[TBL] [Abstract][Full Text] [Related]
23. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Bruland ØS; Nilsson S; Fisher DR; Larsen RH
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
[TBL] [Abstract][Full Text] [Related]
24. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
26. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
[TBL] [Abstract][Full Text] [Related]
27. Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology.
Larsen RH; Saxtorph H; Skydsgaard M; Borrebaek J; Jonasdottir TJ; Bruland OS; Klastrup S; Harling R; Ramdahl T
In Vivo; 2006; 20(3):325-31. PubMed ID: 16724665
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
30. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
31. Radium retention and dosimetry in juvenile beagles.
Lloyd RD; Jones CW; Bruenger FW; Atherton DR; Mays CW
Radiat Res; 1983 May; 94(2):295-304. PubMed ID: 6856775
[TBL] [Abstract][Full Text] [Related]
32. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
[TBL] [Abstract][Full Text] [Related]
33. 188Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake.
Dadachova E; Chapman J
Nucl Med Commun; 1998 Feb; 19(2):173-81. PubMed ID: 9548202
[TBL] [Abstract][Full Text] [Related]
34. Concerning the health effects of internally deposited radionuclides.
Raabe OG
Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
[TBL] [Abstract][Full Text] [Related]
35. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.
Jonasdottir TJ; Fisher DR; Borrebaek J; Bruland OS; Larsen RH
Anticancer Res; 2006; 26(4B):2841-8. PubMed ID: 16886603
[TBL] [Abstract][Full Text] [Related]
36. Preparation, biodistribution, and small animal PET of 45Ti-transferrin.
Vavere AL; Welch MJ
J Nucl Med; 2005 Apr; 46(4):683-90. PubMed ID: 15809492
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for (223)Ra and (225)Ra for targeted alpha therapy.
Rojas JV; Woodward JD; Chen N; Rondinone AJ; Castano CH; Mirzadeh S
Nucl Med Biol; 2015 Jul; 42(7):614-20. PubMed ID: 25900730
[TBL] [Abstract][Full Text] [Related]
38. Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
Harrison JD; Muirhead CR
Int J Radiat Biol; 2003 Jan; 79(1):1-13. PubMed ID: 12556326
[TBL] [Abstract][Full Text] [Related]
39. Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series.
Suliman G; Pommé S; Marouli M; Van Ammel R; Stroh H; Jobbágy V; Paepen J; Dirican A; Bruchertseifer F; Apostolidis C; Morgenstern A
Appl Radiat Isot; 2013 Jul; 77():32-7. PubMed ID: 23511775
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.
Kaspersen FM; Bos E; Doornmalen AV; Geerlings MW; Apostolidis C; Molinet R
Nucl Med Commun; 1995 Jun; 16(6):468-76. PubMed ID: 7675360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
